Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.
Bernies van der HielJohn B A G HaanenMarcel P M StokkelDaniel S PeeperConnie R JimenezJos H BeijnenBart A van de WielRonald BoellaardAlfons J M van den Eertweghnull nullPublished in: BMC cancer (2017)
Clinicaltrials.gov identifier: NCT02414750. Registered 10 April 2015, retrospectively registered.